Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference

Descripción del Articulo

Objective: To determine the relative bioavailability of an oral formulation of multisource sulfamethoxazole 200 mg / 5 ml respect to the reference formulation Oryctolagus cuniculus L (albino rabbits). Material and methods: The samples studied consisted of 25 vials of suspension of sulfamethoxazole /...

Descripción completa

Detalles Bibliográficos
Autores: Alvarado Yarasca, Ángel, Salazar Granara, Alberto, Pineda Pérez, Neuman, Villanueva Vilchez, Hugo, Cáceres Andonaire, Elena
Formato: artículo
Fecha de Publicación:2016
Institución:Universidad de San Martín de Porres
Repositorio:Horizonte médico
Lenguaje:español
OAI Identifier:oai:horizontemedico.usmp.edu.pe:article/465
Enlace del recurso:https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/465
Nivel de acceso:acceso abierto
Materia:Biodisponibilidad relativa
Bioequivalencia
Sulfametoxazol
Medicamento multifuente
Medicamento de referencia
Relative bioavailability
Bioequivalence
Sulfamethoxazole
Multisource drug
Drug reference
id REVHM_cd9bcde7623cd24169765da563ebf943
oai_identifier_str oai:horizontemedico.usmp.edu.pe:article/465
network_acronym_str REVHM
network_name_str Horizonte médico
repository_id_str
dc.title.none.fl_str_mv Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
Estudio de la biodisponibilidad relativa de una formulación multifuente de sulfametoxazol respecto al medicamento referente
title Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
spellingShingle Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
Alvarado Yarasca, Ángel
Biodisponibilidad relativa
Bioequivalencia
Sulfametoxazol
Medicamento multifuente
Medicamento de referencia
Relative bioavailability
Bioequivalence
Sulfamethoxazole
Multisource drug
Drug reference
title_short Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
title_full Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
title_fullStr Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
title_full_unstemmed Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
title_sort Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
dc.creator.none.fl_str_mv Alvarado Yarasca, Ángel
Salazar Granara, Alberto
Pineda Pérez, Neuman
Villanueva Vilchez, Hugo
Cáceres Andonaire, Elena
author Alvarado Yarasca, Ángel
author_facet Alvarado Yarasca, Ángel
Salazar Granara, Alberto
Pineda Pérez, Neuman
Villanueva Vilchez, Hugo
Cáceres Andonaire, Elena
author_role author
author2 Salazar Granara, Alberto
Pineda Pérez, Neuman
Villanueva Vilchez, Hugo
Cáceres Andonaire, Elena
author2_role author
author
author
author
dc.subject.none.fl_str_mv Biodisponibilidad relativa
Bioequivalencia
Sulfametoxazol
Medicamento multifuente
Medicamento de referencia
Relative bioavailability
Bioequivalence
Sulfamethoxazole
Multisource drug
Drug reference
topic Biodisponibilidad relativa
Bioequivalencia
Sulfametoxazol
Medicamento multifuente
Medicamento de referencia
Relative bioavailability
Bioequivalence
Sulfamethoxazole
Multisource drug
Drug reference
description Objective: To determine the relative bioavailability of an oral formulation of multisource sulfamethoxazole 200 mg / 5 ml respect to the reference formulation Oryctolagus cuniculus L (albino rabbits). Material and methods: The samples studied consisted of 25 vials of suspension of sulfamethoxazole / trimethoprim multisource 200 mg: 40 mg / 5 ml T1 with the letter assigned to the batch 11070674; and as a reference (R) 25 flasks Bactrim suspension of 200 mg: 40 mg / 5 ml, RJ0774 batch. The protocol consisted of a single oral dose of 100 mg / kg of sulfamethoxazole 200 mg / 5 ml of each of the formulations to 12 albino rabbits after a 12 hour fasting, through an open design in two cross periods (T / R), randomized, double-blind study with a greater range of 5 half-lives between each administration, later to determine plasma concentrations of the drug in default until 12 hours by means of a spectrophotometric method periods of time colorimetric diazotization. With the data of plasma, bioavailability curves were constructed, including the area under the curve (ABCo-12h , ABCo-∞ ), Cmax and tmax were determined. Results: According to statistical analysis for bioequivalence, it was found: ABCo-12h T1 / ABCo-12h R CI 90% from 0.873 to 1.021, AUCo-∞ T1 / AUCo-∞ R 90% CI 0.868 to 1.032 and Cmax T1 / Cmax R CI 90% 0,866- 1,045. Conclusions: The values of multisource sulfamethoxazole found are within the acceptable range of bioequivalence proposed by WHO and the FDA(0.80-1.25), demonstrating the bioequivalence of multisource T1 respect to the reference.
publishDate 2016
dc.date.none.fl_str_mv 2016-09-27
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/465
10.24265/horizmed.2016.v16n3.03
url https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/465
identifier_str_mv 10.24265/horizmed.2016.v16n3.03
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/465/338
dc.rights.none.fl_str_mv Derechos de autor 2016 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2016 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
dc.source.none.fl_str_mv Horizonte Médico (Lima); Vol. 16 No. 3 (2016): July - September; 12-19
Horizonte Médico (Lima); Vol. 16 Núm. 3 (2016): Julio - Setiembre; 12-19
Horizonte Médico (Lima); v. 16 n. 3 (2016): Julio - Setiembre; 12-19
2227-3530
1727-558X
10.24265/horizmed.2016.v16n3
reponame:Horizonte médico
instname:Universidad de San Martín de Porres
instacron:USMP
instname_str Universidad de San Martín de Porres
instacron_str USMP
institution USMP
reponame_str Horizonte médico
collection Horizonte médico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1845989090612215808
spelling Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug referenceEstudio de la biodisponibilidad relativa de una formulación multifuente de sulfametoxazol respecto al medicamento referenteAlvarado Yarasca, ÁngelSalazar Granara, AlbertoPineda Pérez, NeumanVillanueva Vilchez, HugoCáceres Andonaire, ElenaBiodisponibilidad relativaBioequivalenciaSulfametoxazolMedicamento multifuenteMedicamento de referenciaRelative bioavailabilityBioequivalenceSulfamethoxazoleMultisource drugDrug referenceObjective: To determine the relative bioavailability of an oral formulation of multisource sulfamethoxazole 200 mg / 5 ml respect to the reference formulation Oryctolagus cuniculus L (albino rabbits). Material and methods: The samples studied consisted of 25 vials of suspension of sulfamethoxazole / trimethoprim multisource 200 mg: 40 mg / 5 ml T1 with the letter assigned to the batch 11070674; and as a reference (R) 25 flasks Bactrim suspension of 200 mg: 40 mg / 5 ml, RJ0774 batch. The protocol consisted of a single oral dose of 100 mg / kg of sulfamethoxazole 200 mg / 5 ml of each of the formulations to 12 albino rabbits after a 12 hour fasting, through an open design in two cross periods (T / R), randomized, double-blind study with a greater range of 5 half-lives between each administration, later to determine plasma concentrations of the drug in default until 12 hours by means of a spectrophotometric method periods of time colorimetric diazotization. With the data of plasma, bioavailability curves were constructed, including the area under the curve (ABCo-12h , ABCo-∞ ), Cmax and tmax were determined. Results: According to statistical analysis for bioequivalence, it was found: ABCo-12h T1 / ABCo-12h R CI 90% from 0.873 to 1.021, AUCo-∞ T1 / AUCo-∞ R 90% CI 0.868 to 1.032 and Cmax T1 / Cmax R CI 90% 0,866- 1,045. Conclusions: The values of multisource sulfamethoxazole found are within the acceptable range of bioequivalence proposed by WHO and the FDA(0.80-1.25), demonstrating the bioequivalence of multisource T1 respect to the reference.Objetivo: Determinar la biodisponibilidad relativa de una formulación multifuente oral de sulfametoxazol de 200 mg/5 ml respecto a la formulación referente en Oryctolagus cuniculus L (conejos albinos). Material y métodos: Las muestras estudiadas consistieron en 25 frascos de suspensión de sulfametoxazol/ trimetoprima multifuente de 200 mg: 40 mg/5 ml asignado con la letra T1 para el lote 11070674; y como referente (R) 25 frascos de suspensión de Bactrim de 200 mg: 40 mg/5 ml, lote RJ0774. El protocolo consistió en administrar una dosis oral única de 100 mg/kg de sulfametoxazol de 200 mg/5 ml de cada una de las formulaciones a 12 conejos albinos, después de un ayuno de 12 horas, a través de un diseño abierto, en dos períodos cruzados (T/R), aleatorio y doble ciego, con un intervalo mayor de 5 tiempos de vida media entre cada administración, para determinar posteriormente las concentraciones plasmáticas del fármaco en períodos de tiempo predeterminados hasta las 12 horas por medio de un método espectrofotométrico colorimétrico de diazotación. Con los datos de las concentraciones plasmáticas se construyeron las curvas de biodisponibilidad y de ellas se determinaron el área bajo la curva (ABCo-12h, ABCo-∞), Cmáx y tmáx. Resultados: Según análisis estadístico para bioequivalencia, se encontraron: ABCo-12h T1/ ABCo-12h R IC90% 0,873-1,021, ABC0- T1/ ABC0-∞ R IC90% 0,868-1,032 y Cmáx T1/Cmáx R IC90% 0,866-1,045. Conclusiones: Los valores encontrados de sulfametoxazol multifuente están dentro del rango aceptable de bioequivalencia propuesto por la OMS y la FDA (0,80-1,25), demostrándose la bioequivalencia del multifuente T1 respecto al referente.Universidad de San Martín de Porres. Facultad de Medicina Humana2016-09-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/46510.24265/horizmed.2016.v16n3.03Horizonte Médico (Lima); Vol. 16 No. 3 (2016): July - September; 12-19Horizonte Médico (Lima); Vol. 16 Núm. 3 (2016): Julio - Setiembre; 12-19Horizonte Médico (Lima); v. 16 n. 3 (2016): Julio - Setiembre; 12-192227-35301727-558X10.24265/horizmed.2016.v16n3reponame:Horizonte médicoinstname:Universidad de San Martín de Porresinstacron:USMPspahttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/465/338Derechos de autor 2016 Horizonte Médico (Lima)https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:horizontemedico.usmp.edu.pe:article/4652020-12-29T18:11:02Z
score 13.384119
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).